Roth/MKM Starts Heartbeam Inc. (BEAT) at Buy

Roth/MKM analyst Kyle Bauser initiates coverage on Heartbeam Inc. (NASDAQ: BEAT) with a Buy rating and a price target of $4.00.

The analyst comments: "We are initiating coverage of HeartBeam, Inc. (BEAT) with a Buy rating and $4 price target. BEAT is a medical technology company developing a credit-card-sized, cable-free cardiac device that synthesizes a 12-lead electrocardiogram (ECG). We expect FDA clearance of this technology in the coming days that will initially focus on advanced cardiac arrhythmias within the concierge medicine market. Given the growth in remote patient monitoring (RPM), importance of early detection, and favorable clinical results to date, we believe BEAT shares remain undervalued."

For an analyst ratings summary and ratings history on Heartbeam Inc. click here. For more ratings news on Heartbeam Inc. click here.

Shares of Heartbeam Inc. closed at $1.61 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades Telecom Argentina (TEO) to Overweight
• Arm Holdings (ARM) PT Raised to $475 at TD Cowen
• FedEx (FDX) PT Lowered to $397 at Bernstein SocGen Group